Form 4: Director Marks Acquires AN2 Therapeutics Stock

AN2 Therapeutics Director Gilbert Lynn Marks acquired 9,705 shares of common stock as non-cash compensation, increasing his total beneficial ownership to 41,507 shares.

Summary

• Gilbert Lynn Marks, a Director of AN2 Therapeutics, Inc. (ANTX), acquired 9,705 shares of common stock.
• The transaction occurred on April 10, 2025.
• These shares were issued in lieu of cash compensation under the issuer's non-employee director compensation policy.
• All acquired shares vested immediately.
• Following this transaction, Gilbert Lynn Marks beneficially owns a total of 41,507 shares of AN2 Therapeutics common stock.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director, even as compensation, generally indicates alignment of interests with shareholders. While not a direct cash investment, it contributes to insider ownership and can be viewed as a moderately positive signal.

Positives

• The acquisition of shares by a director aligns their interests with those of the shareholders, promoting long-term value creation.
• The immediate vesting of shares provides the director with immediate ownership and a direct stake in the company's performance.

Negatives

• The shares were acquired at a price of $0, indicating they were compensation rather than a direct cash investment by the director.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Director Gilbert Lynn Marks acquired 9,705 shares of common stock from AN2 Therapeutics, Inc. as compensation, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value due to increased equity ownership.

Key Dates

Recommendation

The transaction represents routine equity compensation for a director and does not provide new fundamental information to alter an investment thesis. It aligns director interests but isn't a strong signal for a buy or sell, as it's not a direct cash investment.

Keywords

AN2 Therapeutics, ANTX, Gilbert Lynn Marks, Director Stock Acquisition, Form 4, Insider Trading, Equity Compensation